Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43234   clinical trials with a EudraCT protocol, of which   7153   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-005775-12
    Sponsor's Protocol Code Number:230LE303
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2021-07-08
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2020-005775-12
    A.3Full title of the trial
    A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care
    Estudio de fase III, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de BIIB059 en participantes adultos con lupus eritematoso sistémico activo que reciben de base tratamiento estándar no biológico para el lupus.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care
    Estudio para evaluar la eficacia y la seguridad de BIIB059 en participantes adultos con lupus eritematoso sistémico activo que reciben de base tratamiento estándar no biológico para el lupus.
    A.4.1Sponsor's protocol code number230LE303
    A.5.4Other Identifiers
    Name:INDNumber:117288
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorBiogen Idec Research Limited
    B.1.3.4CountryUnited Kingdom
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBiogen Idec Research Limited
    B.4.2CountryUnited Kingdom
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationBiogen Idec Research Ltd.
    B.5.2Functional name of contact pointBiogen España
    B.5.3 Address:
    B.5.3.1Street AddressPaseo de la Castellana 41
    B.5.3.2Town/ cityMadrid
    B.5.3.3Post code28046
    B.5.3.4CountrySpain
    B.5.4Telephone number+34913107110
    B.5.5Fax number+3491310781
    B.5.6E-mailclinicaltrials@biogenidec.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameNot applicable
    D.3.2Product code BIIB059
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNot applicable
    D.3.9.2Current sponsor codeBIIB059
    D.3.9.3Other descriptive nameHumanised IgG1 monoclonal antibody against blood dendritic cell antigen 2
    D.3.9.4EV Substance CodeSUB208560
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number150
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typerecombinant monoclonal antibody
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection
    D.8.4Route of administration of the placeboSubcutaneous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    systemic lupus erythematosus
    lupus eritematoso sistémico
    E.1.1.1Medical condition in easily understood language
    Lupus
    Lupus
    E.1.1.2Therapeutic area Diseases [C] - Immune System Diseases [C20]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level PT
    E.1.2Classification code 10042945
    E.1.2Term Systemic lupus erythematosus
    E.1.2System Organ Class 10028395 - Musculoskeletal and connective tissue disorders
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level LLT
    E.1.2Classification code 10025139
    E.1.2Term Lupus erythematosus systemic
    E.1.2System Organ Class 10028395 - Musculoskeletal and connective tissue disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of this study is to demonstrate efficacy of BIIB059 compared with placebo in participants with active systemic lupus erythematosus (SLE), who are receiving background lupus standard of care (SOC) therapy in reducing disease activity.
    Demostrar la eficacia de BIIB059 en comparación con placebo en participantes con LES activo que están recibiendo tratamiento estándar de base para el lupus en la reducción de la actividad de la enfermedad
    E.2.2Secondary objectives of the trial
    The secondary objectives are:
    * to demonstrate:
    - early onset of efficacy of BIIB059 compared with placebo in participants with active SLE, receiving SOC in reducing disease activity;
    - organ-specific efficacy of BIIB059 compared with placebo in participants with active SLE, receiving SOC in reducing joint disease activity;
    - effect of BIIB059 compared with placebo in reducing oral corticosteroid (OCS) use;
    - organ-specific efficacy of BIIB059 compared with placebo in participants with active SLE receiving SOC in reducing skin disease activity and in reducing occurrence of flare up to Week 52;
    *to evaluate:
    - additional efficacy of BIIB059 compared with placebo in reducing disease activity with additional disease activity measures and OCS use
    - the safety, tolerability and immunogenicity of BIIB059 in participants with active SLE;
    * to assess the difference between BIIB059 and placebo on participant-reported HRQoL, symptoms, and impacts of SLE;
    Demostrar la aparición temprana de la eficacia de BIIB059 en comparación con placebo en participantes con LES activo que reciben TE de base para el lupus en la reducción de la actividad de la enfermedad;eficacia específica de cada órgano de BIIB059 en comparación con placebo en participantes con LES activo que reciben TE de base para el lupus en la reducción de la actividad de la enfermedad; efecto de BIIB059 en comparación con placebo en la reducción del uso de CEO3;
    - eficacia de BIIB059 en comparación con placebo en participantes con LES activo que reciben TE de base para el lupus en la reducción de la aparición de exacerbaciones hasta la semana 52; evaluar eficacia adicional de BIIB059 en comparación con placebo en la reducción de la actividad de la enfermedad con mediciones adicionales de la actividad de la enfermedad y
    uso de CEO3; seguridad,tolerabilidad e inmugenia; evaluar la diferencia entre el BIIB059 y el placebo en los informes HRQoL,los síntomas y efectos de LES.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Key Inclusion Criteria:
    - Participant must be diagnosed with systemic lupus erythematosus (SLE) at least 24 weeks prior to screening and must meet the 2019 European League Against Rheumatism (EULAR) / American College of Rheumatology (ACR) classification criteria for SLE at screening by a qualified physician.
    - Participant has a modified Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) score ≥ 6 (excluding alopecia, fever, lupus-related headache, and organic brain syndrome) at screening (adjudicated).
    - Participant has a modified clinical SLEDAI-2K score ≥ 4 (excluding anti-dsDNA, low complement complement component 3 (C3) and/or complement component 4 (C4), alopecia, fever, lupus-related headache, and organic brain syndrome) at Screening (adjudicated) and randomization.
    - Participant has BILAG-2004 grade A in ≥ 1 organ system or BILAG-2004 grade B in ≥ 2 organ systems at Screening (adjudicated) and randomization.
    - Participant must be treated with one of the following background nonbiologic lupus SOC therapies, initiated ≥ 12 weeks prior to Screening and at stable dose ≥ 4 weeks prior to randomization,
    a. Antimalarials as stand-alone treatment
    b. Antimalarial treatment in combination with OCS and/or immunosuppressants
    c. Treatment with OCS and/or immunosuppressants

    Note: Other protocol defined inclusion criteria may apply.
    Criterios de inclusión:
    - clasificación de la EULAR/ACR de 2019 para el LES al menos 24 semanas antes de la selección, realizado un médico cualificado [Aringer 2019].
    - El participante tiene una puntuación SLEDAI-2K modificada ≥6 (excepto alopecia, fiebre, cefalea relacionada con lupus y síndrome cerebral orgánico) en la selección (adjudicada)
    - anticuerpos anti-ADNbc, niveles bajos del complemento C3 o C4, alopecia, fiebre, cefalea relacionada con lupus y síndrome cerebral orgánico) en la selección (adjudicada) y la aleatorización.
    - El participante tiene grado A de BILAG-2004 en ≥1 sistema orgánico o grado B de BILAG-2004 en ≥2 sistemas orgánicos en la selección (adjudicado) y la aleatorización.
    - El participante debe estar tratado con uno de los siguientes tratamientos estándar de base para el lupus no biológicos, iniciados ≥12 semanas antes de la selección y a una dosis estable ≥4 semanas antes de la aleatorización
    a) Antipalúdicos como tratamiento independiente.
    b) Tratamiento antipalúdico en combinación con corticosteroides orales (CEO) y/o inmunodepresores.
    c) Tratamiento con CEO y/o inmunodepresores.
    Nota: Pueden aplicarse otros criterios de inclusión definidos por el protocolo.
    E.4Principal exclusion criteria
    Key Exclusion Criteria:
    - History of or positive test result for human immunodeficiency virus (HIV).
    - Current hepatitis C infection (defined as positive hepatitis C virus (HCV) antibody and detectable HCV ribonucleic acid [RNA]).
    - Current hepatitis B infection (defined as positive for hepatitis B surface antigen (HBsAg) and/or total hepatitis B core antibody [anti-HBc]).
    - History of severe herpes infection.
    - Presence of uncontrolled or New York Heart Association class III or IV congestive heart failure. - Active severe lupus nephritis where, in the opinion of the Investigator, protocol-specified SOC is insufficient and use of a more aggressive therapeutic approach is indicated, such as adding IV cyclophosphamide and/or high-dose IV pulse corticosteroid therapy or other treatments not permitted in the protocol is indicated; or urine protein-creatinine ratio > 2.0 or severe chronic kidney disease (estimated glomerular filtration rate < 30 milliliters per minute per 1.73 meter square [mL/min/1.73 m^2]) calculated using the abbreviated modification of diet in renal disease equation.
    - Any active skin conditions other than cutaneous lupus erythematosus (CLE) that may interfere with the study assessment of CLE such as but not limited to psoriasis, dermatomyositis, systemic sclerosis, non-LE skin lupus manifestation or drug-induced lupus.
    - History or current diagnosis of a clinically significant non-SLE-related vasculitis syndrome.
    - Active neuropsychiatric SLE.
    - Use of oral prednisone (or equivalent) above 20 mg/day.

    Note: Other protocol defined Exclusion criteria may apply.
    Criterios de exclusion:
    - Antecedentes o resultado positivo en la prueba de VIH
    - Infección actual por hepatitis C (definida como positivo de anticuerpo contra el VHC y ARN del VHC detectable).
    - Infección actual de hepatitis B (definida como positivo para HBsAg y/o anti-HBc total).
    - Antecedentes de infección grave por herpes
    - Presencia de insuficiencia cardíaca congestiva incontrolada de clase 3 o 4 según la Asociación de Cardiología de Nueva York
    - Nefritis por lupus grave activa donde, en opinión del investigador, el TE especificado en el protocolo es insuficiente y esté indicado el uso de un enfoque terapéutico más agresivo, como añadir ciclofosfamida i.v. y/o tratamiento con corticosteroides en pulso i.v. en dosis altas u otros tratamientos no permitidos en el protocolo; o cociente proteína-creatinina en orina >2,0 o enfermedad renal crónica grave (tasa de filtración glomerular estimada <30 ml/min/1,73 m 2) calculada utilizando la ecuación abreviada de modificación de la dieta en la enfermedad renal.
    - Cualquier afección cutánea activa distinta del LEC (lupus eritematoso crónico) que pueda interferir en la evaluación del estudio del LEC, como, entre otras, psoriasis, dermatomiositis, esclerosis sistémica, manifestación cutánea de lupus no relacionada con LE o lupus inducido por fármacos..
    - Antecedentes o diagnóstico actual de síndrome de vasculitis no relacionado con la LES clínicamente significativo
    - LES neuropsiquiátrico activo
    - Uso de prednisona oral (o equivalente) por encima de 20 mg/día.

    Nota: Pueden aplicarse otros criterios de exclusión definidos por el protocolo.
    E.5 End points
    E.5.1Primary end point(s)
    Percentage of Participants Who Achieved a Systemic Lupus Erythematosus Responder Index of 4 (SRI-4) Response at Week 52.
    • Proporción de participantes que lograron una respuesta SRI-4 en la semana 52.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Week 52
    semana 52
    E.5.2Secondary end point(s)
    1. Percentage of Participants Who Achieved an SRI-4 Response at Week 24
    2. Percentage of Participants With at Least 4 Joints (Both Swollen and Tender) at Baseline Who Achieved a Joint-50 Response at Week 52
    3. Percentage of Participants with OCS ≥10 milligrams per day (mg/day) at Baseline Who Have OCS Reduction to ≤7.5 mg/day at Week 40, Which Is Sustained Through Week 52 with No Disease Worsening from Week 40 to Week 52
    4. Percentage of Participants with a CLASI-A score ≥10 at Baseline Who Achieved a 50% Improvement From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity Score (CLASI-50) Response at Week 16
    5. Annualized Flare Rate Through Week 52
    6. Change from Baseline in Physician’s Global Assessment (PGA) Visual Analog Scale (VAS) Score by Visit
    7. Percentage of Participants Who Achieved a British Isles Lupus Activity Group (BILAG)-Based Combined Lupus Assessment (BICLA) Response by Visit
    8. Time to Onset of SRI-4 Response Sustained Through Week 52
    9. Percentage of Participants Who Achieved SRI-4, -5, or -6 Response by Visit
    10. Percentage of Participants with Joint-50 Response by Visit
    11. Percentage of Participants with Baseline CLASI-A Score ≥10 Who Achieved a CLASI-20, -50, -70, or -90 Response by Visit
    12. Percentage of Participants with Baseline CLASI-A Score ≥10 Who Achieved a CLASI-A Score of ≤ 1 by Visit
    13. Time to First British Isles Lupus Activity Group-2004 (BILAG-2004) Severe Flare by Visit
    14. Time to First Severe Flare as defined by the Safety of Estrogens in Systemic Lupus Erythematosus National Assessment - Systemic Lupus Erythematosus Disease Activity Index Flare Index (SFI)
    15. Percentage of Participants With Baseline OCS ≥10 mg/day Who Achieved ≤7.5 mg/day at Week 52
    16. Change from Baseline in Lupus-Specific Health-Related Quality-of-Life Questionnaire (LupusQoL) Score
    17. Change From Baseline in Short Form Health Survey-36 (SF-36) Score
    18. Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score
    19. Change From Baseline in Patient Health Questionnaire-9 (PHQ-9) Score
    20. Change From Baseline in Work Productivity and Activity Impairment (WPAI): Lupus Score
    21. Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
    22. Number of Participants with Antibodies to BIIB059
    1. Proporción de participantes que lograron una respuesta SRI-4 en la semana 24.
    2. Proporción de participantes con al menos 4 articulaciones (tanto inflamadas como sensibles) al inicio que lograron una respuesta Joint-501,2 en la semana 52.
    3. Proporción de participantes con CEO ≥10 mg/día al inicio que presentan una reducción de CEO a ≤7,5 mg/día en la semana 40, que se mantiene hasta la semana 52 sin empeoramiento de la enfermedad4 desde la semana 40 hasta la semana 52.
    4. Proporción de participantes con una puntuación CLASI-A ≥10 al inicio que lograron una respuesta CLASI-505 en la semana 16.
    5. Tasa anualizada de exacerbaciones6 hasta la semana 52.
    6. Cambio desde el inicio en la puntuación de PGA-EVA por visita.
    7. Proporción de participantes que lograron una respuesta de BICLA por visita.
    8. Tiempo hasta el inicio de la respuesta SRI-4 sostenida hasta la semana 52.
    9.Proporción de participantes que lograron una respuesta SRI-4, -5 o -6 por visita.
    10.Proporción de participantes con respuesta Joint-501,2 por visita.
    11.Proporción de participantes con una puntuación CLASI-A ≥10 al inicio que lograron una respuesta CLASI-20, -50, -70 o -90 por visita.
    12.Proporción de participantes con una puntuación CLASI-A ≥10 al inicio que lograron una respuesta CLASI-A de ≤1 por visita.
    13. Tiempo hasta la primera exacerbación grave de BILAG-2004, donde se define la exacerbación grave mediante la definición de BILAG
    14. Tiempo hasta la primera exacerbación grave según el SFI, durante el periodo de tratamiento doble ciego controlado con placebo, donde se define la que la exacerbación grave utilizando la definición del SFI
    15. Proporción de participantes con uso de CEO al inicio ≥10 mg/día que alcanzaron ≤7,5 mg/día en la semana 52.
    16. LupusQoL, SF-36 (versión aguda), FACIT-Fatiga, PHQ-9 y WPAI:Lupus.
    21. Incidencia de AAG y AAST.
    22. Incidencia de anticuerpos contra BIIB059
    E.5.2.1Timepoint(s) of evaluation of this end point
    1. wk 24
    2. wk 52
    3. wk 40 up to wk 52
    4. wk 16
    5. up to wk 52
    6. up to wk 52
    7. up to wk 52
    8. up to wk 52
    9. up to wk 52
    10. up to wk 52
    11. up to wk 52
    12. up to wk 52
    13. up to wk 52
    14. up to wk 52
    15. wk 52
    16. up to wk 52
    17. up to wk 52
    18. up to wk 52
    19. up to wk 52
    20. up to wk 52
    21. up to wk 52
    22. up to wk 52
    1. semana 24
    2. semana 52
    3. semana 40 hasta semana 52
    4. semana 16
    5. hasta semana 52
    6. hasta semana 52
    7. hasta semana 52
    8. hasta semana 52
    9. hasta semana 52
    10. hasta semana 52
    11.hasta semana 52
    12. hasta semana 52
    13. hasta semana 52
    14. hasta semana 52
    15. semana 52
    16. hasta semana 52
    17. hasta semana 52
    18. hasta semana 52
    19. hasta semana 52
    20. hasta semana 52
    21. hasta semana 52
    22. hasta semana 52
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    immunogenicity and tolerability
    Inmunogenia y tolerabilidad
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA36
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Brazil
    Chile
    Korea, Republic of
    Mexico
    Peru
    Philippines
    Russian Federation
    Taiwan
    United States
    Bulgaria
    France
    Greece
    Poland
    Spain
    Sweden
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LSLV
    UVUS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years5
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days13
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months4
    E.8.9.2In all countries concerned by the trial days4
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 528
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 12
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state13
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 138
    F.4.2.2In the whole clinical trial 540
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Participants who successfully complete the 52-week treatment
    period with study treatment are treatment period completers. Treatment period completers will be offered to either participate in the LTE study or enter the 24-week SFU. The LTE study is not part of this study and is planned to be developed as a separate protocol.
    Los participantes que completan con éxito el periodo de tratamiento de 52 semanas
    con el tratamiento del estudio son los que completan el periodo de tratamiento. A los que completen el periodo de tratamiento se les ofrecerá participar en el estudio ELP o entrar en el SFU de 24 semanas. El estudio ELP no forma parte de este estudio y está previsto que se desarrolle como un protocolo independiente.
    G. Investigator Networks to be involved in the Trial
    G.4 Investigator Network to be involved in the Trial: 1
    G.4.1Name of Organisation DrugDev
    G.4.3.4Network Country United States
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-10-05
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-10-01
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2023 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA